Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes ...

Endogenex today announced new findings supporting its technology for improving outcomes in individuals with type 2 diabetes.

New trial data indicates that Tegoprubart, a CD40L-selective humanized monoclonal antibody, may help protect transplanted islet cells while avoiding the toxicities of calcineurin ...

Eledon Pharmaceuticals, Inc. ("Eledon”) (NASDAQ: ELDN) today announced updated results from an investigator-initiated trial con ...

Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume if the medication was not held prior to upper endoscopy, unless they were on a clear liquid diet the previous day, ...

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) - ...

New research suggests root canal treatment may do more than save your teeth. Scientists are exploring how this common dental procedure could help reduce the risk of heart disease and diabetes through ...

News and commentary from the endocrinology world ...

Currently on a Mounjaro injectable, he wants to get rid of it some day and doesn’t want it to define his life. “It got me off a dangerous ledge called obesity, made me confident, made me do things ...